header logo image


Page 1,022«..1020..1,0211,0221,0231,024..1,0301,040..»

SSCI Receives a 2017 Biotechnology Award for Global Research and Manufacturing – Yahoo Finance

April 27th, 2017 10:41 am

WEST LAFAYETTE, Ind., April 26, 2017 /PRNewswire/ --SSCI, a division of Albany Molecular Research Inc. (AMRI), has been recognized by Global Health & Pharma (GHP) magazine as the winner of the 2017 Biotechnology Award for Best Global Research & Manufacturing Company in the United States.

"I am truly honored to accept this award on behalf of our dedicated team that is deeply committed to the mission of helping our clients achieve their product development goals and generate valuable intellectual property day in and day out," said David A. Engers, Ph.D., general manager at SSCI. "We are grateful to GHP for recognizing our commitment to client service and data integrity in order to provide unmatched value to the industries we have served for more than a quarter century."

GHP magazine recognizes that the biotechnology industry is increasingly viewed as being the frontline of medical science, and as this movement continues to gain momentum the publication is committed to following the most game-changing advances and revolutionary developments that will form the healthcare world for years to come.

Nathan Angell, GHP awards coordinator, expressed pride in every one of the award winners, "This award recognizes the hard work and dedication of the firms, such as SSCI, and the individuals behind them, that are driving innovation in this vital market. It has been my honor to recognize these dedicated professionals and I would like to wish them the very best of fortunes for the future."

About SSCIAMRI SSCI, LLC (SSCI), a division of AMRI, provides industry leading contract solid-state and analytical testing services and exists to help companies in the pharmaceutical, food, agrochemical, and other chemical industries develop better products and get them to market more quickly. SSCI provides comprehensive cGMP research and analytical services in the characterization and chemistry of solid materials, with particular expertise in small and large molecules being investigated for pharmaceutical use.To learn more about SSCI's solid-state and analytical chemistry services and capabilities,please contact 1-800-375-2179 | http://www.ssci-inc.com.

About GHP MagazineGlobal Health and Pharma (GHP) magazine is a global, information-sharing platform and a multi-disciplinary members community. The publication was established to enhance communication networks and collaboration across all themes and disciplines within three main categories; Human, Animal and Environmental Health.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ssci-receives-a-2017-biotechnology-award-for-global-research-and-manufacturing-300445541.html

The rest is here:
SSCI Receives a 2017 Biotechnology Award for Global Research and Manufacturing - Yahoo Finance

Read More...

3D Systems and United Therapeutics to Develop 3D Printing Biotechnology for Solid-Organ Scaffolds – 3DPrint.com

April 27th, 2017 10:41 am

No matter how many times I read or write about it, I am still overwhelmed and amazed when I see what 3D printing technology is currently able to do for the medical field, and what it has the potential to do down the line. Today, 3D Systems, a company thats nearly synonymous with precision healthcare capabilities, and biotechnology company United Therapeutics Corporation announced a joint plan to develop solid-organ scaffolds for use in human transplants. The multi-year development and collaboration is a good fit, combining 3D Systemshealthcare and 3D printing expertise with the organ manufacturing and regenerative medicine proficiency of United Therapeutics, which is also a member of the consortium that makes up the Advanced Tissue Biofabrication Manufacturing USA Institute.

Vyomesh Joshi, CEO of 3D Systems, said, As a global leader in healthcare solutions, we are part of many developments and applications for 3D printing coming together including bioprinting.We believe bioprinting is a powerful opportunity and we are uniquely positioned with the broadest portfolio of technologies to partner with companies of the caliber of United Therapeutics to provide healthcare solutions of the future.

In addition to collaborating with United Therapeutics, which is focused on developing and commercializing products that address the medical needs of patients living with chronic and life-threatening conditions, 3D Systems will also work with its organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC, which is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Through several technologies that expand the supply or delay the need for transplantable organs, Lung Biotechnology PBC addresses head-on the critical shortage of transplantable lungs, and other organs, in the US. Withthe subsidiary also on board with the 3D Systems collaboration, an additional technology alternative can be added to United Therapeutics pursuit of an unlimited supply of organs for human transplantation.

Dr. Martine Rothblatt, PhD, Chairman and CEO of United Therapeutics, said, Our Lung Biotechnology public benefit corporation is taking personal regenerative medicine to its highest level yet with this practical, economic solution to a major health care problem.Indeed, we expect one personalized organ transplant will avoid years of health care spending on palliative medical therapies.

The focus of the joint bioprinting agreement is to develop 3D printing systems for solid-organ scaffolds, and with Lung Biotechnology PBCs participation, obviously the first thing the companies will tackle is lung scaffolds. Scaffolds are an important part of the bioprinting process, as they give printed cells, and organs, a structure to develop and grow on. So determining the correct way to create a scaffold is incredibly important to the success of these endeavors.

Combiningthe resources of United Therapeutics and 3D Systems transforms our capability to tackle this difficult challenge.This project will be based out of our new bioprinting lab in San Diego, CA, and will rely on expertise across many technical disciplines within 3D Systems as well as the domain knowledge of our technical partners at Lung Biotechnology PBC, said Chuck Hull, Executive Vice President and Chief Technology Officer for 3D Systems.

The 3D printing system that 3D Systems and United Therapeutics hope to create will be targeting collagen, along with other building block proteins, as the raw materials for the scaffolds themselves. In turn, Lung Biotechnology PBC will then celluralize the scaffolds using patient-specific biological material, which includes re-differentiated stem cells.

Our partnership with 3D Systems is a major step forward in creating an unlimited supply of tolerable transplanted organs.By cellularizing scaffolds created with 3D Systems printers with a patients own cells, there will no longer be a need for immunosuppression and a vastly greater number of patients can extend their enjoyment of life through organ transplantation, said Dr. Rothblatt.

[Image: OPTN]

Here is the original post:
3D Systems and United Therapeutics to Develop 3D Printing Biotechnology for Solid-Organ Scaffolds - 3DPrint.com

Read More...

250598 Shares in Puma Biotechnology Inc (PBYI) Acquired by Norges Bank – The Cerbat Gem

April 27th, 2017 10:41 am
250598 Shares in Puma Biotechnology Inc (PBYI) Acquired by Norges Bank
The Cerbat Gem
Puma Biotechnology logo Norges Bank acquired a new position in Puma Biotechnology Inc (NYSE:PBYI) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 250,598 shares of the biopharmaceutical ...
-$2.08 EPS Expected for Puma Biotechnology Inc (PBYI) This QuarterSports Perspectives
Analyst Observation On 2 Stocks: Delta Technology (DELT), Puma Biotechnology (PBYI)Post Analyst

all 4 news articles »

Excerpt from:
250598 Shares in Puma Biotechnology Inc (PBYI) Acquired by Norges Bank - The Cerbat Gem

Read More...

Use of biotechnology must to attain food security: Bosan | Pakistan … – Pakistan Today

April 27th, 2017 10:41 am

Around 130 national and international academicians and scientists hailing from seven different countries including Turkey, Tunisia, Sudan, Iran, Sri Lanka, and Uzbekistan attended a workshop held here to promote the safe use of modern biotechnology to attain the goal of food security and defeating hunger and poverty.

Minister for Food Security and Research Sikandar Hayat Khan Bosan inaugurated the 3rd International Conference on Agriculture, Food Security and Biotechnology on Wednesday.

The 2-day event being held at the National Agriculture Research Center, Islamabad, is jointly organised by Commission on Science and Technology for Sustainable Development in the South (COMSATS), ISESCO and Pakistan Agricultural Research Council (PARC).

Addressing the audiences, the minister said that it was time that the countries of the region should encourage and support smart agricultural practices.

He said safe use of modern biotechnology was needed to enhance agricultural production and get rid of malnutrition and starvation. The minister pledged full support for agricultural production which was the backbone of economy with sustainable food security.

Dr Ghulam Muhammad Ali, Member Coordination and Monitoring, PARC, Islamabad, noted that advances in science and technology were the need of time for food security and safety. Noting the hunger still prevailing in various parts of the world, he opined that biotechnology was the basis of production of vast variety of transgenic and genetically modified crops which can solve the problem of hunger.

He said that the conference having similar agenda was good for the developing countries as it would open ways for research, collaboration and capacity building.

Speaking on the occasion, Dr Kauser Malik, Department of Biological Sciences, FC College Lahore, mentioned that it was our fear of unknown that kept the human beings away from adapting new technologies and advocated the use of genetically modified crops for addressing hunger.

In his message, Dr SM Junaid Zaidi, Executive Director COMSATS, said that despite major developments around the globe, many areas struggle with challenges of starvation and malnutrition. Even the developed countries cannot engage in bigger pursuits without ensuring food security. Mentioning the importance of biotechnology in agriculture, he noted that biotechnological influence on food production and agriculture is undeniable especially for countries like Pakistan with fertile lands and good weather conditions.

The message from Director General ISESCO, HE Dr. Abdulaziz Othman Altwaijri, noted that there was a dire need to provide an enriching and engaging environment to foster crop science research towards new and improved livelihood opportunities and sustainable food security. He considered collaborations in this regard necessary and appreciated the cooperation between ISESCO and COMSATS.

Shields were given to the esteemed participants who came from different countries for the conference.

See the original post:
Use of biotechnology must to attain food security: Bosan | Pakistan ... - Pakistan Today

Read More...

3D Systems and United Therapeutics partner to 3D print organ scaffolds for human transplants – TCT Magazine

April 27th, 2017 10:41 am

3D Systems has announced a bioprinting agreement with United Therapeutics which will see the two companies develop solid-organ scaffolds for human transplants with 3D printing.

Combining their respective expertise in 3D printing and regenerative medicine and organ manufacturing, the collaboration will remain for a number of years.

The agreement will pit 3D Systems personnel alongside professionals from a United Therapeutics subsidiary, Lung Biotechnology PBC. Since the collaboration will primarily focus on the development of 3D printing systems for solid-organ lung scaffolds, Lung Biotechnology PBC is seen as best placed to work with 3D Systems.

The printing system will target collagen, and other building block proteins, as scaffold raw materials. Lung Biotechnology PBC will cellularize the scaffolds with patient-specific biological material, including re-differentiated stem cells.

Our partnership with 3D Systems is a major step forward in creating an unlimited supply of tolerable transplanted organs, said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. By cellularizing scaffolds created with 3D Systems printers with a patients own cells, there will no longer be a need for immunosuppression and a vastly greater number of patients can extend their enjoyment of life through organ transplantation.

3D Systems is a company with a wealth of experience in the medical sector. Its precision healthcare capabilities include simulation, virtual surgical planning, and the printing of medical and dental devices. Two of 3D Systems leading executives are not only confident in their companys own knowledge of the medical 3D printing sector, but also of United Therapeutics own expertise. Though conceding the challenge is not straight forward, the pair foresee new solutions being born from the partnership.

As a global leader in healthcare solutions, we are part of many developments and applications for 3D printing coming together including bioprinting, said Vyomesh Joshi, Chief Executive Officer, 3D Systems. We believe bioprinting is a powerful opportunity and we are uniquely positioned with the broadest portfolio of technologies to partner with companies of the calibre of United Therapeutics to provide healthcare solutions of the future.

Chuck Hull, Executive Vice President, Chief Technology Officer, 3D Systems, added: Combining the resources of United Therapeutics and 3D Systems transforms our capability to tackle this difficult challenge. This project will be based out of our new bioprinting lab in San Diego, CA, and will rely on expertise across many technical disciplines within 3D Systems as well as the domain knowledge of our technical partners at Lung Biotechnology PBC.

Meanwhile, the collaboration and joint development will add another technology alternative to United Therapeutics pursuit of an unlimited supply of organs for human transplantation.

Dr Rothblatt concludes: Our Lung Biotechnology public benefit corporation is taking personal regenerative medicine to its highest level yet with this practical, economic solution to a major health care program. Indeed, we expect one personalised organ transplant will avoid years of health care spending on palliative medical therapies.

Go here to see the original:
3D Systems and United Therapeutics partner to 3D print organ scaffolds for human transplants - TCT Magazine

Read More...

Walk to Cure Arthritis slated for May 20 at Woodlawn High School – The Advocate

April 27th, 2017 10:41 am

More than 200 walkers are expected to lace up their shoes for the Arthritis Foundations Walk to Cure Arthritis, beginning at 8 a.m. May 20 at Woodlawn High School.

Arthritis is the nations leading cause of disability and affects 1.2 million residents of Louisiana, including 6,000 children, a news release said.

Special guests will include youth honoree Charlotte Collins; adult honoree Danielle Thibodaux; corporate chairman Dr. Joseph E. Broyles, of the Bone and Joint Clinic of Baton Rouge; and medical honoree Dr. Stephen Pollet, of The Baton Rouge Clinic.

Walk to Cure Arthritis provides people the opportunity to experience the power of standing together and giving back to the community. Together, Baton Rouge can Walk to Cure Arthritis and help us reach our goal of raising $45,000 to help find a cure for this disease, Broyles said.

Visit walktocurearthritis.org/batonrouge or call Sara Morthland at (337) 540-0615 to register.

Read more:
Walk to Cure Arthritis slated for May 20 at Woodlawn High School - The Advocate

Read More...

Arthritis news: Condition can cause BLINDNESS in sufferers – Express.co.uk

April 27th, 2017 10:41 am

GETTY

Uveitis - a condition causing inflammation in the middle layer of the eye - is most common in those aged 20 to 59, and affects two to five people in every 10,000 in the UK each year.

If left untreated, the inflammation can cause blindness, and according to Prevent Blindness its one of the leading causes of loss of sight in the world in those of working age.

Many cases are linked to problems with the immune system, including arthritis.

One type, juvenile idiopathic arthritis (JIA), was the subject of a breakthrough study which discovered a new way to prevent children with arthritis and eye disease losing their sight.

GETTY

The results of the trial revealed how the drug could reduce eye inflammation and stop serious complications, including blindness.

The results of the trial - the first of its kind in the world, and funded by Arthritis Research UK and the National Institute for Health Research - revealed how a drug called Adalimumab, in combination with Methotrexate, could reduce eye inflammation and stop serious complications, including blindness.

In fact, the findings, published in The New England Journal of Medicine, were so ground-breaking the trial was stopped early due to convincing evidence.

It has already led to changes in guidelines, and the drug has since been approved by NHS England for use, set to help thousands of people.

Professor Ramanan from University Hospitals Bristol NHS Foundation Trust and University of Bristol said: Uveitis in children is an important cause of loss of vision. This study demonstrates the benefit of Adalimumab in children with uveitis. This is the first randomised trial of its kind worldwide and the results will have a major impact in children with uveitis all around the world."

GETTY

1 of 9

The study authors found 75 per cent of children with JIA-associated uveitis who were treated with Adalimumab experienced a significant reduction in eye inflammation.

Stephen Simpson, director of research and programmes at Arthritis Research UK said: We are thrilled of the outcome of this trial and the huge promise it heralds for transforming the quality of life for the large numbers of children with JIA-associated uveitis. This trial is an impressive example of how investing in exceptional science can ultimately help change how treatment is delivered with direct and immediate benefit for patients.

In those of any age with arthritis, the condition can affect one or both eyes and may develop suddenly, or gradually over a few days.

According to the NHS, symptoms include eye pain, eye redness, sensitivity to light, blurred or cloudy vision and loss of peripheral vision.

GETTY

Uveitis may not also affect the whole eye - just part.

It can be at the front of the eye, middle of the eye and back of the eye, and the symptoms may vary for each.

Currently the main way to treat uveitis is using steroid medication. Eye drops are used if the front of the eye is affected, while injections, tablets and capsules are used to treat it at the middle and back.

While uveitis can affect anyone, a study this month published in JAMA Ophthalmology found those with psoriasis are at an increased risk of developing it.

See original here:
Arthritis news: Condition can cause BLINDNESS in sufferers - Express.co.uk

Read More...

Study Reveals Important Advance for Newly Diagnosed Rheumatoid Arthritis Sufferers – National Pain Report

April 27th, 2017 10:41 am

By Staff

New research out of The Universities of Manchester and East Anglia shows that people living with Rheumatoid Arthritis (RA) experience significant improvement in their daily lives due to early and more aggressive treatment of the disease.

The Arthritis Research UK study examined 20 years of data between 1990 and 2010. A total of 602 patients participated in the study led by James Gwinnutt, from The University of Manchester and Dr. Suzan Verstappen University of Manchester.

Participants were recruited to the Norfolk Arthritis Register and assessed at regular intervals over the course of 20 years.

They found that patients who were prescribed disease modifying drug therapies such as sulfasalazine, methotrexate and steroids within 6 months of symptom onset experienced significantly better ability to walk, grip and dress themselves over the course of 20 years compared, to patients who were treated later.

This research shows that patients who received treatment early after symptom onset had similar levels of disability over the subsequent 20 years compared to patients who were judged by clinicians not to require treatment, after accounting for the differences in disease severity between the groups, Gwinnutt said.

Though there is a broad range in terms of how people are affected by the disease, the number of patients whose lives have improved has increased thanks in part to early treatment. The good news is that early intervention has become more and more common in the NHS over these past 20 years. In the early 1990s early intervention would happen in about 30% of cases. Nowadays, that figure is probably more like 60-70%. Theres no reason why this improvement could not extend further, he added.

Dr Natalie Carter, head of research liaison and evaluation at Arthritis Research UK, said:

Rheumatoid arthritis is an incredibly painful condition that can be diagnosed at any age and can have an impact on a persons everyday life. This study confirms how important early diagnosis and the commencement of treatment is. It is also encouraging to hear about the progress that has been made over the last 20 years. Now the scientific community must continue to build on this so that together we can continue to harness the power of exceptional science and make everyday life better for all people with arthritis.

Rheumatoid arthritis is an autoimmune disease that causes joint inflammation and pain.

More:
Study Reveals Important Advance for Newly Diagnosed Rheumatoid Arthritis Sufferers - National Pain Report

Read More...

Rheumatoid arthritis: Obesity skews markers of inflammation – Nature – Nature.com

April 27th, 2017 10:41 am
Rheumatoid arthritis: Obesity skews markers of inflammation - Nature
Nature.com
BMI is positively associated with an elevated C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR) in women with rheumatoid arthritis (RA), ...

and more »

See the article here:
Rheumatoid arthritis: Obesity skews markers of inflammation - Nature - Nature.com

Read More...

Early treatment gets better results for rheumatoid arthritis | Health24 – Health24

April 27th, 2017 10:41 am

26 April 2017 Early treatment gets better results for rheumatoid arthritis Researchers found that patients who were treated within six months of developing the first signs of rheumatoid arthritis did better in the long run.

Rheumatoid arthritis is a chronic autoimmune condition distinguished by inflammation of the peripheral joints of the hands, wrists, elbows, shoulders, hips, knees and feet, usually on both sides of the body.

Treating rheumatoid arthritis early may make for better outcomes, a new study suggests.

Early death less likely

Patients who were treated within six months of developing the first signs of the autoimmune disease did better in the long run and were less likely to suffer early death, British researchers found.

The findings stem from an analysis of more than 600 patients who were initially diagnosed with rheumatoid arthritis (RA) between 1990 and 1994. They were tracked for over 20 years.

Over the study time frame, investigators assessed key symptoms of RA, such as swollen and/or tender joints, and indications of disability. All deaths were also noted.

The research team found that patients who started treatment for RA within the first half-year after the first symptoms surfaced tended to have no greater levels of disability over a 20-year period than patients who required no treatment.

A better future

And while roughly 44% of the patients died during the study period, the team observed that early treatment translated into a notably lower mortality risk.

The findings were published online in the journal Arthritis & Rheumatology.

"This research emphasises the importance of early treatment and the long-term benefits of early treatment," study author Dr Suzanne Verstappen, from the University of Manchester, said in a journal news release.

"In the early 1990s," she added, "when this study started, only 30% of patients received early treatment, but this number has increased significantly in the last decade.

"It's expected that in the next 10 years, newly diagnosed patients will have a better future with respect to functional ability, less severe disease activity and improved quality of life," Verstappen said.

Read more:

Risks of rheumatoid arthritis

Rheumatoid arthritis vs. osteoarthritis

Symptoms of osteoarthritis

Professor Asgar Ali Kalla completed his MBChB (Bachelor of Medicine and Bachelor of Surgery) degree in 1975 at the University of Cape Town and his FRCP in 2003 in London. Professor Ali Kalla is the Isaac Albow Chair of Rheumatology at the University of Cape Town and also the Head of Division of Rheumatology at Groote Schuur Hospital. He has participated in a number of clinical trials for rheumatology and is active in community outreach. Prof Ali Kalla is an expert in Arthritis for Health24.

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

Thanks! Check your inbox to complete your subscription

Test

Are you at risk for arthritis?

Quiz

Test your knee pain knowledge

Arthritis symptoms check - part 1

Arthritis symptoms check - part 2

Excerpt from:
Early treatment gets better results for rheumatoid arthritis | Health24 - Health24

Read More...

Kelly Osbourne Campaigning to Make Stem Cell Therapy Affordable … – Hollywood.com

April 27th, 2017 10:40 am

Wenn

Singer-turned-TV personality Kelly Osbourne wants to help cure fellow Lyme disease sufferers by making stem cell therapy available for all in the U.S.

Ozzy and Sharon Osbournes daughter contracted the condition after she was bitten by a tick during a party for the rockers 56th birthday back in 2004, when her mother had a reindeer sanctuary installed at their Los Angeles home.

However, Kelly wasnt properly diagnosed until 2014, months after suffering a seizure while filming an episode of E!s Fashion Police show in 2013, when doctors claimed her collapse had been caused by epilepsy.

She did some research into her ailments and discovered she was actually struggling with Lyme disease, and promptly sought out alternative treatment to help her overcome the illness.

I started to actually do the one thing doctors tell you not to do and thats to go online and look it up, she explained on Good Morning America, and all roads pointed to Lyme disease so I found a doctor through my mum.

I went to Frankfurt, Germany, and I did stem cell (therapy) and I got cured, Kelly claimed.

The 32-year-old is lucky to have been in a position to afford the treatment, which involves the transplant of stem cells to heal those damaged by the disease, and now she is looking to get involved in making the therapy more widely available and affordable to others less fortunate.

It sickens me that thats not available to everyone and that you have to be considered lucky or privileged to get that sort of treatment, she said. I want to make sure and I will do anything that I can do to make sure that that treatment is available in this country.

Kelly details her experience with the bacterial infection in her new memoir There Is No F**king Secret: Letters from a Bada** B**ch. She isnt the only celebrity to open up about her struggles with Lyme disease pop star Avril Lavigne, and veteran model Yolanda Hadid and her runway star kids Bella and Anwar Hadid have also been battling the illness.

See the original post:
Kelly Osbourne Campaigning to Make Stem Cell Therapy Affordable ... - Hollywood.com

Read More...

Are baby, wisdom teeth the next wave in stem cell treatment? – FOX 61

April 26th, 2017 10:43 am

FOX 61
Are baby, wisdom teeth the next wave in stem cell treatment?
FOX 61
Alison Bassetto's voice is steady and brisk as she explains why her husband's untimely death prompted her to have her 19-year-old son's wisdom teeth banked. The practice of cryopreserving children's baby or wisdom teeth is one that's been around for a ...

and more »

View original post here:
Are baby, wisdom teeth the next wave in stem cell treatment? - FOX 61

Read More...

California’s deadly ‘social legislation’ parallels its economic and … – Desert Dispatch

April 26th, 2017 10:43 am

By Richard Reeb

The Golden States well-known descent from its years of prosperity and political clout, which stands in sharp contrast to the nations recently renewed growth and turn to the right, has another side. That is its Democrat leaders determination to facilitate the death of unwanted unborn babies, the elderly and terminally ill. Indeed, this session of the California State Legislature provides more evidence of this ominous trend. We Californians already legalize and finance abortion on demand and last year sanctioned so-called assisted suicide. Now attention is turning to new means and new victims of this misguided movement.In the State Senate, four bills have been introduced to this end, while one constitutional amendment has been proposed to stem the billions in funding for embryonic stem cell research. First, the bill (SB 743) of Sen. Richard Pan, D-Sacramento, would guarantee that Planned Parenthood and other abortion providers could still receive federal Medicaid funds via Medi-Cal family planning services. This is a perfect example of California Democrats defiance of the national conservative trend. Fortunately, it will probably go nowhere as President Donald Trump has recently rescinded his immediate predecessors executive order to force states to finance abortions. Exemplifying abortion advocates virtual sanctification of fetal homicide is SB 309, originally introduced by Sen. Pan, which would actually establish a specialty license plate celebrating reproductive freedom. Revenue generated would go to the California Reproductive Freedom Fund, whatever that is. One wonders: did the Third Reich authorize plates for Volkwagens to celebrate the killing of members of inferior races? Sen. Pans SB 481 would allow nursing homes to declare patients unfit to make their own decisions, and then implement medical procedures which may include assisted suicide. The state already permits persons believed to be facing deathin six monthsto end their lives, justified on the grounds of their own consent. This new development demonstrates just how hollow that premise was. While unlikely to make it out of committee, Senate Constitutional Amendment 7 would repeal the (embryonic) Stem Cell Research and Cures Act approved by the states voters in 2004. That misguided measure was sold on the failed promise that embryonic cells offered the greatest potential. But experience with adult stem cells and from placentas has been far more fruitful. Though not directly aimed at death, SB 18, also the work of Sen. Pan, originally sought to challenge parental authority in the name of childrens rights. Of course, parents natural concern for their childrens very lives cannot be surpassed. Yet this bill would have directly threatened parents ability to provide in-home education for their children or to send them to private schools. But Senate committee action has changed the focus of the bill to establish an 18-member Children and Youth joint committee (half from the Senate and half from the Assembly) to direct the legislature to maximize spending on that class of persons. It would undo current code on this subject by the year 2025. The original alarming objectives doubtless will be implemented in bits and pieces through the new committees efforts. Do only children who have been permitted to be born deserve this intense concern? Meanwhile, California's new Attorney General Xavier Becerra has slapped 15 felony charges 14 counts of illegally recording conversations without consent and one count of conspiracy against David Daleiden, the project lead at the Center for Medical Progress (CMP), and his associate Sandra Merritt. In the past 20 months, the Center for Medical Progress has released a series of undercover videos that feature high end Planned Parenthood officials and employees of tissue procurement companies associated with the nation's largest abortion provider. They admitted in recorded conversations various illegalities about how the companies skirted state and federal law to engage in the selling of highly-desired aborted baby tissue, organs and limbs. "At the end of the day, the only thing that is different from the work that I did and the work that CMP did and the work that undercover journalists and investigative journalists are doing every single day here in California ... is who I went after," Daleiden said during a telephone interview with the Washington Times. "The only difference is that I happened to go after and expose the political ally and financial backers of the establishment power structure in California and in the country. That is the only reason why I am being prosecuted with these bogus charges under California Penal Code 632 and why the local reporters with NBC Los Angeles and other places are not. That really says it all." One can only hope that Californias political leadership would be as zealous in saving lives as they are in ending them. But alas they are not. Such is the situation in our coming sanctuary state.

Richard Reeb taught political science, philosophy and journalism at Barstow College from 1970 to 2003. He is the author of "Taking Journalism Seriously: 'Objectivity' as a Partisan Cause" (University Press of America, 1999). He can be contacted at rhreeb@verizon.net

Original post:
California's deadly 'social legislation' parallels its economic and ... - Desert Dispatch

Read More...

SUPERHUMANS: Mars ‘will be colonised by genetically engineered Star Trek-style beings’ – Express.co.uk

April 26th, 2017 10:43 am

GETTY STOCK IMAGE

The way to the Red Planet and other mysterious worlds is being inspired by the villainous Khan from the blockbuster films, according to new research.

The use of stem cell technology may mean the difference between life and death on any attempt to travel beyond Earth into the wilderness of space.

So the first person to walk on Mars is likely to be selected from the growing group of people whose parents took the step to store their child's stem cells at birth.

Stem cells are 'blank' cells that can be reprogrammed to turn into any other cell in the body, enabling the replacement of damaged cells.

More and more British parents, including TV presenter Natalie Pinkham and dancer Darcey Bussell, are paying more than 2,000 to freeze samples from their babies' umbilical cords at birth.

Stem cells are also found in bone marrow and some body tissue, but the procedure to harvest them from umbilical cords is less risky.

Adventurous Mars pioneers will have to be especially prepared for the dangerous trip, which could expose them to cancer and other diseases, through carefully researched gene therapy.

1 of 16

We wince at the thought of genetically engineered humans

Mark Hall

Mark Hall, spokesperson for the UK's leading stem cell storage and diagnostics company StemProtect, said: "We wince at the thought of genetically engineered humans.

"And we are not going to create a Khan from Star Trek specifically to get to another planet. Getting humans to Mars and beyond will be both expensive and dangerous.

"But the scientific by-products - such as huge leaps in stem cell medicine - will benefit humanity for centuries to come."

Genetic engineering has featured in two Star Trek movies, and a number of TV episodes.

IG

1 of 14

This still image strikes an uncanny resemblance to a figure of a woman

Khan, who appeared in Space Seed and Star Trek II: The Wrath of Khan, was modified to make him stronger and to give him greater stamina and intellectual capacity than a regular human.

Mr Hall said: "The first human to walk on Mars may not even be born yet - but that's an advantage."

StemProtect believes advanced medical techniques will be required to cope with the rigours of interplanetary space.

While a trip to Mars may appear "just around the corner" in galactic terms, it is highly possible exposure to radiation along the way could lead to the astronauts developing leukaemia and other cancers even before they arrived.

GETTY STOCK IMAGE

This means future travellers will have to be 'immunised' before they leave Earth.

Mr Hall said: "There was an article in The Times suggesting elephants would make ideal Martian travellers because they'd be largely immune to the radiation.

"But those laughing at the ridiculous sounding headline completely missed the point - the fact is scientists are already working on ways of getting humans there and back alive."

Recent research has shown radiation in deep space increase the risk of leukaemia while long term exposure to micro gravity may leave astronauts open to infection.

The three year round trip to Mars would affect humans at the stem cell level, leaving them with a drastically lowered immune system, NASA funded scientists say.

And NASA's own findings say stem cells may be crucial to the future of space travel, particularly how they respond in a low gravity environment.

One study showed stem cells flown in space and then cultured back on Earth had greater ability to self renew and generate any cell type, changing more easily into specialised heart muscle cells, for instance.

Mr Hall said an astronaut will have to be prepared for the journey "quite literally at the stem cell level."

He explained: "That means working with the best and most effective stem cells available to the patient - those harvested from the umbilical cord at birth."

GETTY STOCK IMAGE

The therapies required to 'immunise' humans to space travel are still being researched.

And with most space based science, it can only mean huge benefits to mankind back down on Earth when it comes to fighting otherwise deadly conditions and diseases.

Stem cells have the ability to treat a potentially infinite range of illnesses and diseases.

Stem cell therapy is already being used all over the world to treat some cancers and stroke victims - and there is fast progress being made in many other areas, including Parkinson's and Alzheimer's disease.

See more here:
SUPERHUMANS: Mars 'will be colonised by genetically engineered Star Trek-style beings' - Express.co.uk

Read More...

INTERNATIONAL: Mexico eliminates leading cause of blindness – St. Lucia News Online (press release)

April 26th, 2017 10:43 am

PRESS RELEASE Trachoma has been eliminated as a public health problem in Mexico, the World Health Organization (WHO) announced today.

Mexico becomes the first country in the Americas and the third in the world after Oman and Morocco to receive validation from WHO for having eliminated this disease.

Trachoma is the leading infectious cause of blindness worldwide. It is transmitted by contact with bacteria in the eye and nasal discharges of infected persons, especially young children. It affects poor, isolated populations in 41 countries around the world. In the Americas, trachoma is still endemic in Brazil, Guatemala, and Colombia.

Mexico has managed to eliminate trachoma as a public health problem, said WHO Director-General Margaret Chan in a letter to the Mexican Government congratulating the country on the achievement. WHOs conclusion is based on the data presented in the country record and on the recommendation of the review group of independent experts which visited the country last November, she added.

This is a historic moment for public health in Mexico and the Americas, said Carissa F. Etienne, Director of the Pan American Health Organization (PAHO), WHO regional office for the Americas. Eliminating a disease is not achieved every day, she said, acknowledging the decades-long efforts of Mexican authorities, health workers and communities to improve their health and quality of life, and end this disease of poverty.

In Mexico, the disease has been endemic in 246 communities in five municipalities in the state of Chiapas, affecting a total of 146,207 people. Actions to combat trachoma were strengthened in 2004 with the creation of the Trachoma Prevention and Control Program of the Ministry of Health of Chiapas and the strengthening of the WHO SAFE strategy.

This strategy consists of a comprehensive package of interventions including surgery for advanced disease, antibiotics to clear C. trachomatis infection, facial cleanliness and environmental improvement to reduce transmission.

The Trachoma Brigades, a group of doctors, nurses and specially trained technical personnel to combat trachoma, worked locally to reduce the number of cases from 1,794 in 2004 to zero cases in 2016, according to data from the Chiapas Trachoma Prevention and Control Program.

Using this approach, the country met the international criteria for elimination of trachoma as a public health problem, which are: Prevalence of less than 5 percent in children aged 1 to 9, and less than one case oftrachomatous trichiasis (inverted eyelashes) per 1,000 inhabitants.

In 2012, there were only 36 cases of infection among children from 1 to 9 years of age (less than 5%) and less than 1 case of trachomatous trichiasis per 1,000 inhabitants. These numbers met the international criteria for elimination of trachoma as a public health problem.

The Secretary of Health of Mexico, Jose Narro, said he was excited at the achievement of elimination. The accomplishment, he said, was due to A long history of hard work and efforts by many persons, over the course of generations.

To maintain elimination and prevent a resurgence of the disease, PAHO / WHO recommends continuous monitoring of trachoma and delivery of care to affected patients.

To date, five other countries (China, Gambia, Ghana, Iran and Myanmar) have reported on the achievement of elimination targets. Most countries with trachoma are using the SAFE strategy to eliminate the disease by 2020. In 2015, more than 185,000 people with trichiasis received corrective surgery worldwide, and 56 million were treated with antibiotics for trachoma.

This elimination in Mexico adds to another important achievement reached by the country in 2015, when it received the verification of the elimination of onchocerciasis from WHO. Onchocerciasis is a parasitic disease that can also cause blindness and disability and, like trachoma, mainly affects people living in poverty.

This article was posted in its entirety as received by stlucianewsonline.com. This media house does not correct any spelling or grammatical error within press releases and commentaries. The views expressed therein are not necessarily those of stlucianewsonline.com, its sponsors or advertisers.

More here:
INTERNATIONAL: Mexico eliminates leading cause of blindness - St. Lucia News Online (press release)

Read More...

How Orbis is Bringing the World Together to Fight Blindness | 3BL … – 3BL Media (press release)

April 26th, 2017 10:43 am

3BL Media (press release)
How Orbis is Bringing the World Together to Fight Blindness | 3BL ...
3BL Media (press release)
Imagine the world around you in darkness. For millions of people this darkness is a reality. Blindness takes away so much more than vision. It can impede your ...

and more »

See the rest here:
How Orbis is Bringing the World Together to Fight Blindness | 3BL ... - 3BL Media (press release)

Read More...

Pac-Man meets biotechnology – Phys.Org

April 26th, 2017 10:42 am

April 26, 2017 The authors artwork, illustrating the article, was also featured on the cover of Lab on a Chip. Credit: Royal Society of Chemistry

Scientists in the U.S have a designed a computer game that could help with biomedical research.

Scientists increasingly use miniscule robots to solve a range of problems, from cancer treatment to water purification. And, as with a lot of technology, the race is on to make these devices ever smaller.

However there is a limit to how far you can go with a mechanical device moving parts such as motors can physically only get so small.

So scientists are looking to the natural world to help. Single cell organisms, such as bacteria and algae, could make the parts in the miniaturised robots move, without the need for an external power source.

Such organisms respond to changes in their environment such as light and food by moving, and if these movements can be harnessed, we can use them as motors.

In a new paper just published in Lab on a Chip, Ingmar Riedel-Kruse and fellow scientists from Stanford University in the U.S. have demonstrated the use of one such organism, in the form of a game.

It's based on Euglena gracilis, single cell algae that move in response to changes in strong light. In the game, the organisms are directed around a maze or "captured" in a space on the screen by the users turning lights on and off. The ability to control the movement of the algae demonstrates their potential application in mini, single cell organism-driven motors.

In this set-up, the algae's movements are programmable a promising first step towards creating a microcomputer built on biotechnology.

Explore further: Single cell organism firm joins top ranks of Japan bourse

More information: Amy T. Lam et al. Device and programming abstractions for spatiotemporal control of active micro-particle swarms, Lab Chip (2017). DOI: 10.1039/C7LC00131B

The high-tech titans of Japanese industry were joined Wednesday in the major league of the Tokyo Stock Exchange by a company exploiting the 500-million-year-old science of a single cell organism.

Diatoms are unicellular algae that are native in many waters. They are a major component of marine phytoplankton and the food base for a large variety of marine organisms. In addition, they produce about one fifth of the ...

A new 3-D printed, easily assembled smartphone microscope developed at Stanford University turns microbiology into game time. The device allows kids to play games or make more serious observations with miniature light-seeking ...

Scientists at the John Innes Centre have discovered that Euglena gracilis, the single cell algae which inhabits most garden ponds, has a whole host of new, unclassified genes which can make new forms of carbohydrates and ...

Scientists at the Swedish Museum of Natural History have found fossils of 1.6 billion-year-old probable red algae. The spectacular finds, publishing on 14 March in the open access journal PLOS Biology, indicate that advanced ...

In an algae-eat-algae world, it's the single-celled photosynthetic organisms at the top (layer of the ocean) that absorb the most sunlight. Underneath, in the sublayers, are cryptophyte algae that must compete for photons ...

Being first in a new ecosystem provides major advantages for pioneering species, but the benefits may depend on just how competitive later-arriving species are. That is among the conclusions in a new study testing the importance ...

Giacomo Cavalli's team at the Institute of Human Genetics (University of Montpellier / CNRS), in collaboration with the French National Institute for Agricultural Research (INRA), has demonstrated the existence of transgenerational ...

(Phys.org)A pair of researchers with Harvard and Yale Universities has conducted a study of optimal human throwing techniques and found which work best under which conditions. In their paper published in the journal Royal ...

Biologists at the University of California San Diego have demonstrated for the first time that a widely used pesticide can significantly impair the ability of otherwise healthy honey bees to fly, raising concerns about how ...

Newborn humpback whales and their mothers whisper to each other to escape potential predators, scientists reported Wednesday, revealing the existence of a previously unknown survival technique.

New genes are more likely to appear on the stage of evolution in full-fledged form rather than gradually take shape through successive stages of "proto genes" that become more and more refined over generations. This is the ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more here:
Pac-Man meets biotechnology - Phys.Org

Read More...

Top 5 Vendors in the Biotechnology Reagents Market From 2017 to 2021: Technavio – Yahoo Finance

April 26th, 2017 10:42 am

LONDON--(BUSINESS WIRE)--

Technavio has announced the top five leading vendors in their recent global biotechnology reagents market report. This research report also lists four other prominent vendors that are expected to impact the market during the forecast period.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170425006359/en/

The global biotechnology market is a continuously growing market and has witnessed a speedy growth in past few years. The increase in bio-related technologies, research labs, and centers and commercial requests are the main reasons behind the growth of the global biotechnology reagents market. Increasing investment in R&D of biotechnology, from private and government sector, is the key driver for the growth of the global biotechnology reagents market.

Competitive vendor landscape

According to the report, the global biotechnology reagents market consists of a sizeable number of key global players, along with regional and local players. These players have a vast geographical presence with huge production facilities located, globally. There are a considerable number of small regional vendors with significant shares in the market

The major players compete depending on the innovations, price, and quality of the product. Some players can capture the market due to lower costs compared to their competitors. Also, few suppliers financial, technological, and other resources are better as compared with their competitors who can adapt to the changes in the market demand, says Ajay Adhikari, a lead bio-chemicals and bio-materials research analyst from Technavio.

Looking for more information on this market? Request a free sample report

Technavios sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Top five biotechnology reagents market vendors

Agilent Technologies

Agilent Technologies is one of the leading companies in the biotechnology reagents market. The company produces control reagents, blocking reagents, buffers, diluents, and lysing, fixation, and permeabilization reagents.

BD

BD is one of the major biotechnology reagents producing companies. The company offers reagents for research, clinical, and custom services. It provides reagents for various applications such as immunoassays, cell-based assays, and clinical research.

Merck

Merck is one of the largest biotechnological reagents manufacturing companies. The company provides a wide range of reagents and solvents for different functions such as DNA and RNA synthesis, in vitro diagnostics, and instrumental inorganic analysis.

Bio-Rad Laboratories

Bio-Rad is one of the key vendors for the biotechnology reagents market. The company provides biotechnology reagents for clinical diagnostics, PCR technology, protein assay, and immunodetection reagents.

Thermo Fisher Scientific

Thermo Fisher Scientific is one of the key vendors in the biotechnology reagents market. The company offer reagents for various applications such as an immunogenic adjuvant, protein gel buffers, nucleic acid gel buffers, flow cytometer buffers and reagents, immunoassay buffers and reagents, protein purification buffers, and diagnostic testing.

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as theyre published in addition to all 6,000+ existing reports covering segments like industrial gases, olefins, and metals and minerals. This subscription nets you thousands in savings, while staying connected to Technavios constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170425006359/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/news/home/20170425006359/en/

See the rest here:
Top 5 Vendors in the Biotechnology Reagents Market From 2017 to 2021: Technavio - Yahoo Finance

Read More...

Skepticism About Biotechnology Isn’t Anti-Science – Slate Magazine

April 26th, 2017 10:42 am

AquAdvantage salmon.

AquAdvantage

Keep Frankenfish off my Dish! a protesters sign read. Another, adorned with six red hearts, suggested that real people love real salmon. A couple of years ago, protests against the approval and sale of genetically modified salmon targeted the Food and Drug Administration and supermarket chains across the country, attempting to halt the approval and sale of the AquAdvantage salmonan Atlantic salmon modified with DNA from the Chinook salmon and the ocean pout. The borrowed genetic material lets the fish grow year-round and reach market size in half the time as its natural counterpart, but its also spurred passionate public debate.

In November 2015, the FDA approved the AquAdvantage salmon as the first genetically engineered animal for human consumption. According to the hype, the AquAdvantage salmon could help with reducing global hunger, decreasing the carbon footprint of aquaculture (the cultivation of fish and other aquatic life), and shoring up dwindling wild fish stock. The regulatory process behind the approval of the AquAdvantage salmon took almost 20 years.

But the approval was quickly followed by a flurry of controversy and charges of insufficient consideration of key issues. A consortium of environmental groups lead by Earthjustice and the Center for Food Safety sued the FDA for approving the AquAdvantage salmon, in their words, without considering or fullydisclosing the environmental and other risks of this unprecedented decision. Two months after the approval, Congress also threw a wrench in the works by adding a rider to a spending bill that tasked the FDA with spending not less than $150,000 to develop labeling and implement a program of consumer disclosure for the fish before it could be made available for sale. As a result the fish is not yet anywhere near U.S. dinner plates, caught up in a seemingly endless process of contestation, with no clear end in sight.

To many in bioscience and biotechnology circles, this is a case of politics contaminating science. In an open letter to President Obama in 2014, a group of concerned international scientists and global technology company executives argue this point:

These scientists and others offer a picture of a Manichean world divided into those who are for scientific and technological progress and those who are against ita representation of the world that we have been seeing more and more of lately in reports of a war on science. But drawing this line is dangerous. The real problem here is the regulatory process itself, which forces dissent to take the narrow form of challenges to scientific data and methodology and ignores other questions about whats at stake.

The FDA approval process for the AquAdvantage salmon took longer and included more opportunities for public comment than most products the FDA reviews. This unique openness to public input was balanced by a careful parsing of what counts as scientifically and contextually relevant and what does not. The agency received 38,000 comments in response to its draft assessment alone, but it determined that just 90 were worth considering. The remaining comments were discounted as irrelevant because they did not directly address the details of the regulation process, or they raised issues beyond the mandate of the agency. These disregarded comments focused on a wide range of concerns, including patenting and ownership regimes of seed and crops; how deploying genetically modified corn and soy would affect the United States image around the world; continuing failures of existing market configurations to address inequality and food distribution; and the long history of multinational corporations central to the commercialization of biotechnologies, such as Monsanto, intentionally obscuring the negative impacts of their chemical products and byproducts while undermining human health.

Your Cheat-Sheet Guide to Synthetic Biology

What Exactly Is Synthetic Biology? Its Complicated.

Can You Patent an Organism? The Synthetic Biology Community Is Divided.

The U.S. Regulations for Biotechnology Are Woefully Out of Date

Synthetic Biology and Queer Theory Are Cutting Down the Tree of Life You Learned About in School

Being Skeptical About Biotechnology Doesnt Make You Anti-Science

So the FDA is not the forum for deliberation on the meaning of giving entry to this new form of life into our environment, grocery stores, and dining rooms. But what is? The FDA approval process is the only existing avenue for public consideration of technological innovation of this kind. Accordingly, the agencys narrow reading of what kinds of input are relevant represents a significant dismissal of a broad range of relevant concerns.

Some might read the vast public preoccupation with a broad set of social, political, and economic issues as the contamination of science with politics. But I would suggest that this is actually a case of the reverse problem: seemingly endless conflict around the AquAdvantage salmon reflects the limitation of using narrow scientific terms to address questions of broad social, political, and economic significance. As things stand, the only legitimate way to engage in debates about the entry of the AquAdvantage salmon and other genetically modified organisms into our environments, meals, intellectual property regimes, and beyond is to contest its approval at the level of regulatory science. When the system asks the public to limit objections to narrow technical concerns, it undermines regulatory legitimacy and stultifies democratic debateand perhaps most importantly, it contributes to the problematic discourse around science itself. When our modes of public deliberation strictly define what counts as a legitimate view on these issues, we end up portraying a good portion of the population as against science, when that in fact could not be further from the truth.

The vast majority of people in the world, not being scientists or angel investors, have no say over the technological trajectories that will shape our world and our lives. We are instructed to continue funding basic science and patiently wait and watch as the world is transformed around us. Scientists often dismiss resistance to the AquAdvantage salmon and other biotechnologies as borne of scientific ignorance. But its a lot easier to understand peoples reluctance if you realize that the debate is about much broader questions than science alone can answer.

To position science on one side of these debates is not only patently false but detrimental to public discourse.

As the first genetically engineered animal developed for human consumption, the AquAdvantage salmon can be understood as an early form or precursor to products of more advanced practices of synthetic biology. Even as the power and precision of these techniques increases and the particular technical challenges associated with the salmon are left behind, the core issues and deep public resistance around the AquAdvantage salmon will likely persist and haunt continued efforts to reshape environments, economies, and human life through the biological sciences. Synthetic biology is billed as having the potential to transform the world in a way that will disrupt prevailing economic and geopolitical paradigms and reshape the very fabric of life. The one thing both sides of the fishy debate seem to agree on is that the AquAdvantage salmon is a pioneer technology, and what happens to this fish could set the stage for the role that biotechnology will play in our food system in the century to come. As one commentator opined for the New York Times:

This framing suggests that biotechnological innovation is a necessary and unmitigated good. But for many, the prospect of a world radically altered by biotechnology conjures past experiences in which scientific progress didnt go as plannedlike the devastation and political instability ushered in by nuclear weapons. Similarly, to some, a dam looks like progress, development, and economic prosperity. But to others, it looks like the violent end of a way of life, heralded by the destruction of ecosystems and entire species.

The debates over the AquAdvantage salmon arent narrow and technicaltheyre multifaceted, laden with questions of political, economic, and social values. They are about what kind of world we want to live in and what types of transformations are beneficial, desirable, and helpfuland for whom. To position science on one side of these debates is not only patently false but detrimental to public discourse and productive political deliberation.

Nonetheless, resistance to biotechnologies is often framed as a problem of the uneducated masses meddling in areas where they dont belong. The open letter to Obama by the concerned scientists and technologists, for example, claims:

Characterizing legitimate concerns about what kinds of technologies enter and help shape our world as anti-science is more likely to alienate than inspire everyday Americans to identify with this vision of what science can do, and to believe in it.

The long journey of the AquAdvantage salmon may turn out to have been a waste of time, energy, and resources on all sides, but perhaps we can make it productive in one way. Understanding the limitations of the process can help us think critically about how decision-making about synthetic biology going forward might be more open to a broader set of concerns and voices much earlier in the innovation process. The way forward is not drawing battle lines between those who are for or against science and closing down regulatory processes to all but the narrowest risk-based considerations. Rather, we should be forming and expanding spaces for a wide range of participants in creatively considering how to solve societys biggest challenges. We need new ways of thinking and talking about technological promise and possibility in the world that we live in.

This article is part of the synthetic biology installment of Futurography, a series in which Future Tense introduces readers to the technologies that will define tomorrow. Each month, well choose a new technology and break it down. Future Tense is a collaboration among Arizona State University, New America, and Slate.

Originally posted here:
Skepticism About Biotechnology Isn't Anti-Science - Slate Magazine

Read More...

Global Biotechnology Reagents Market to Grow at a CAGR of 10.13 … – Yahoo Finance

April 26th, 2017 10:42 am

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Global Biotechnology Reagents Market 2017-2021" report to their offering.

The global biotechnology reagents market to grow at a CAGR of 10.13% during the period 2017-2021.

The report, Global Biotechnology Reagents Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Ready-to-use reagents help minimize calculation, dilution, and pipetting errors. They reduce the duration of the diagnostic procedure and prevent contamination of samples. These factors have resulted in the demand for ready-to-use reagents among clinical laboratories and hospitals.

According to the report, the biotechnology industry is spending a huge amount on R&D to innovate new techniques and technologies. The companies are more focused to improve the products, their quality, and standards. The biotech companies are majorly spending on protein synthesis, drug assessment, therapeutics, DNA and RNA analysis, and cell culture applications. Biotechnology reagents are used in all the processes.

Key vendors

Other prominent vendors

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Market segmentation by technology

PART 07: Market segmentation by application

PART 08: Geographical segmentation

PART 09: Decision framework

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Key vendor analysis

PART 14: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/j8h37n/global

View source version on businesswire.com: http://www.businesswire.com/news/home/20170425005769/en/

Read the original here:
Global Biotechnology Reagents Market to Grow at a CAGR of 10.13 ... - Yahoo Finance

Read More...

Page 1,022«..1020..1,0211,0221,0231,024..1,0301,040..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick